Bicara Therapeutics BCAX Share-Based Payment - Unrecognized Cost of Nonvested Awards
Share-Based Payment - Unrecognized Cost of Nonvested Awards at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's share-based payment - unrecognized cost of nonvested awards.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's share-based payment - unrecognized cost of nonvested awards?
- Bicara Therapeutics (BCAX) reported share-based payment - unrecognized cost of nonvested awards of $72.5M in Q1 2026.
- How has Bicara Therapeutics's share-based payment - unrecognized cost of nonvested awards changed year-over-year?
- Bicara Therapeutics's share-based payment - unrecognized cost of nonvested awards increased by 112.6% year-over-year, from $34.1M to $72.5M.
- What does share-based payment - unrecognized cost of nonvested awards mean?
- This represents the total compensation expense for equity-based awards that has been granted but not yet recognized in the income statement because the vesting conditions have not been met. It serves as a forward-looking indicator of future non-cash compensation expenses. Investors use this to forecast the impact of stock-based compensation on future earnings.